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Original Article
Multiple risk factors for diabetes mellitus in
patients with chronic pancreatitis: A
multicentre study of 1117 cases
Søren S Olesen1,2 , Jakob L Poulsen1,2 , Srdan Novovic3,
Camilla Nøjgaard3, Evangelos Kalaitzakis4, Nanna M Jensen5,
Trond Engjom6,7, Erling Tjora8,9, Anne Waage10, Truls Hauge11,12,
Stephan L Haas13, Miroslav Vujasinovic13, Giedrius Barauskas14,
Aldis Pukitis15, Imanta Ozola-Zālı̄te15, Alexey Okhlobystin16,
Mikael Parhiala17,18, Johanna Laukkarinen17,18 and Asbjørn
M Drewes1,2 for the Scandinavian Baltic Pancreatic Club
Abstract
Background: Diabetes mellitus is a common complication of chronic pancreatitis. It is traditionally considered to
develop as a consequence of beta cell loss, but there might be additional factors. Recent studies have highlighted
the importance of type 2 diabetes-related risk factors in this context and population-based studies show increased
risk of diabetes following acute pancreatitis. The aim of this study was to explore multiple risk factors for diabetes
in patients with chronic pancreatitis.
Methods: We conducted a multicentre, cross-sectional study of patients with definitive chronic pancreatitis accord-
ing to the M-ANNHEIM criteria. We used multivariable logistic regression models to determine risk factors inde-
pendently associated with diabetes.
Results: The study included 1117 patients of whom 457 (40.9 %) had diabetes. The mean age was 52.8 14.2 years
and 67% were men. On multivariate analysis, parameters indicative of beta cell loss (pancreatic calcification,
exocrine insufficiency, pancreatic resection) were confirmed as independent risk factors for diabetes (all
p 0.02). In addition, type 2 diabetes-related risk factors (dyslipidaemia and overweight/obesity) were associated
with the presence of diabetes (all p 0.002). Patients with a history of pancreatic fluid collections (indicative of
previous attacks of acute pancreatitis) had a marginally increased risk of diabetes (p¼ 0.07).
Conclusion: In patients with chronic pancreatitis the presence of diabetes is associated with multiple risk factors
including type 2 diabetes-related factors. Our observations attest to the understanding of this entity and may have
implications for treatment.
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Key Summary
Summarise the established knowledge on this subject:
. Diabetes mellitus (DM) is a common complication of chronic pancreatitis.
. Factors indicative of beta cell loss are well-established risk factors for DM.
. Type 2 DM-related risk factors and a history of acute pancreatitis may increase the risk of DM.
What are the significant and/or new findings of this study?
. We confirmed risk factors for DM indicative of beta cell loss (pancreatic exocrine insufficiency, pancreatic
calcifications, and pancreatic resection).
. Type 2-related risk factors (overweight/obesity and dyslipidaemia) conveyed an independent risk of DM.
. A history of acute pancreatitis only marginally influenced the risk of DM.
Introduction
Chronic pancreatitis (CP) is a fibro-inflammatory dis-
ease characterized by progressive replacement of
the pancreatic parenchyma with fibrotic tissue.1
Development of pancreatic exocrine insufficiency
(EPI) and diabetes mellitus (DM) are foreseeable com-
plications of CP and affects a large proportion of
patients.2 Whereas EPI typically develops as a result
of acinar cell destruction and/or obstruction of the pan-
creatic duct, the mechanisms underlying DM in the
context of CP are incompletely understood and likely
involve a number of mechanisms in addition to reduced
beta cell mass following destruction of islet cells.3,4
Recent studies have highlighted the importance of
type 2 DM-related risk factors in patients with CP.3,5
Accordingly, Bellin et al. characterized a number of risk
factors for diabetes in a large multicentre cohort study
of CP patients from North America.3 The risk factors
included classic CP-related parameters such as EPI, cal-
cifications and pancreatic resection (indicative of beta
cell loss), and type 2 DM-related risk factors such as a
family history of diabetes, dyslipidaemia as well as
overweight or obesity (indicative of beta cell dysfunc-
tion and/or insulin resistance). In keeping with these
findings, another study showed that genetic risk
scores based on validated single nucleotide polymorph-
isms for type 2 DM were similar in CP and type 2 DM
patients, but distinct from genetic risk scores in a
non-diabetic control population.5 As such, beta cell
dysfunction and insulin resistance may be important
mechanisms of DM in patients with CP in addition to
beta cell loss.6
Population-based studies have shown that patients
with a history of acute pancreatitis (but without CP)
have a more than two-fold increased risk for developing
DM compared with the background population.7,8 As
many patients with CP have a history of recurring acute
pancreatitis, the mechanisms underlying DM following
acute pancreatitis may also be relevant in patients with
CP.9,10 However, previous studies have not explored
this hypothesis, and the mechanisms underlying DM
in patients with CP are probably multifactorial but
incompletely understood (Figure 1).
We investigated risk factors for DM in a multicentre
cohort of more than 1100 patients with CP. We
hypothesized that type 2 DM-related risk factors and
a history of recurring acute pancreatitis would be asso-
ciated with an increased risk of DM independently of
classic CP-related diabetes risk factors. The aims of the
study were: a) to determine the point prevalence of DM
in a well-characterized Northern European cohort of
CP patients and b) to define risk factors for DM
using multivariable statistical modelling in combination
with comprehensive assessment of acute and CP-related
parameters as well as type 2 DM-related risk factors.
Methods
This was a cross-sectional, multicentre study based on
the Scandinavian Baltic Pancreatic Club (SBPC) data-
base. This database include data from a multicentre
prospective registration of patients with CP initiated
on 1 February 2016,11 we derived data for the present
study as of 12 August 2019. The dataset included regis-
trations from 11 centres in eight countries, a detailed
description of the methodology and study protocol of
the SBPC database is provided in a previous publica-
tion.11,12 The M-ANNHEIM classification system was
used to define CP and only patients with a definite
diagnosis of CP (histology and/or pancreatic calcifica-
tions and/or marked pancreatic duct pathology
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(Cambridge grade 3 or 4)) were included.13 These cri-
teria were chosen to ensure a uniform characterization
of our study cohort and to exclude patients with DM
following acute pancreatitis (but without definite evi-
dence of CP).7
The study protocol conforms to the ethical guide-
lines of the 1975 Declaration of Helsinki. The Centre
for Pancreatic Disease at Aalborg University Hospital,
Denmark served as the coordinating center. In agree-
ment with Danish law and recommendations from the
North Denmark Region Committee on Health
Research Ethics, our study did not require written or
informed consent because this was a register-based
study and no study-related procedures were underta-
ken. Approval for data collection and storage was
obtained from the Danish Data Protection Agency,
Northern Denmark Region (2008-58-0028, project ID
2018–19).
Study assessment parameters
We retrieved information on patients’ demographics,
aetiology and duration of CP, presence of EPI and
DM, medical treatment as well as history of recurring
acute pancreatitis based on review of medical records
and patient interviews. Weight and height were mea-
sured and body mass index (BMI) calculated as
weight divided by height squared. The World Health
Organization classification for BMI was adopted for
categorization of BMI into four subgroups: under-
weight BMI (BMI<18.5 kg/m2), normal BMI (18.5–
24.9 kg/m2), overweight BMI (25.0–29.9 kg/m2) and
obese BMI (>30 kg/m2).14 The treating physician
designated the most likely aetiological risk factor(s)
according to the M-ANNHEIM system, no absolute
risk-thresholds for smoking and alcohol consumption
were adopted in this process.13 A diagnosis of DM was
based on the criteria commenced by the
American Diabetes Association.15 We used the faecal
elastase concentration test, C13 mixed triglyceride
breath test or faecal fat collection to characterize exo-
crine pancreatic function according to local practice at
the individual sites. We defined EPI according to pre-
viously published criteria.16 We reviewed imaging stu-
dies as part of routine clinical practice and information
on pancreatic calcifications and pancreatic duct path-
ology was registered on the database. We retrieved
information on endoscopic and surgical treatment
from patient interviews and reviews of medical records.
The following endoscopic procedures were registered:
a) drainage procedures of pancreatic fluid collections
(indicative of previous attacks of acute pancreatitis);
b) common bile duct stenting and stone clearance;
and c) stenting and stone clearance of the pancreatic
duct. Surgery included: a) drainage procedures; b) pan-
creatic resection; and c) combined drainage and resec-
tion procedures.
Statistical analysis
We present data as numbers (%) for categorical vari-
ables and means (standard deviations (SD)) for con-
tinuous variables. We inspect QQ plots to determine
if continuous variables are normally distributed and
compare patient demographics and disease characteris-
tics for CP patients with and without DM using
Student’s t-test for continuous variables and Fisher’s
exact test for categorical variables (univariate analysis).
We use multivariable logistic regression with backward
selection to assess the variables independently asso-
ciated with the presence of DM and the TRIPOD rec-
ommendations are adopted in the design of statistical
modelling.17 Variables are included and removed one at
a time according to their significance level (p< 0.15)
Type 2 DM related risk factors:
• Overweight/obesity
• Dyslipidaemia
• Family history (genetic predisposition)
Implicated mechanisms:
• Beta cell dysfunction
• Insulin resistance





• Beta cell loss
Acute pancreatitis related risk factors:
• History of (recurring) acute pancreatitis
• Pancreatic fluid collections
Implicated mechanisms:
• Unknown
Diabetes in patient with
chronic pancreatitis
Figure 1. Putative risk factors and implicated mechanisms for diabetes mellitus in patients with chronic pancreatitis.
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until a final model is reached. In case a variable is con-
sidered to have clinical relevance, it is forced back into
the model (history of recurring acute pancreatitis). The
interaction between BMI categories and the presence of
EPI is determined using a nested log-likelihood test,
comparing a model containing the variables as single
terms with a model also including the interaction
term.18 Results from multivariate analyses are pre-
sented as odds ratios (ORs) with 95% confidence inter-
vals (CI). A significance threshold of p< 0.05 is used.
The software package STATA version 16.0 (StataCorp
LP, College Station, Texas, USA) is used for all statis-
tical analyses.
Results
A total of 1322 patients were eligible for the study and
among these complete datasets for DM and other rele-
vant variables were available for 1117 patients (final
study cohort). Included patients had a mean age of
52.8 14.2 years at the time of CP diagnosis and 750
(67%) were men. We report the detailed characteristics
of the study cohort in Table 1 and CP related treatment
modalities in Table 2. The most frequent etiological risk
factors were smoking (67%) and excessive alcohol
consumption (59%), whereas nutritional risk factors
(dyslipidaemia) were only present in a small proportion
of patients (4%).
Prevalence of DM and antidiabetic treatment
DM was evident in 457 of the 1117 included patients,
which corresponds to a point prevalence of 40.9%
(95% CI, 38.0–43.9%). The majority of patients with
DM were treated with insulin-based therapies (56%) or
oral antidiabetics (25%), with 10% of diabetics receiv-
ing both oral antidiabetics and insulin (Table 2).
A small proportion of patients with DM (9%) were
managed without antidiabetic drugs; some of them
were newly diagnosed with DM and consequently had
not yet received treatment.
Single parameters associated with DM
(univariate analysis)
Results of the univariate analysis are reported in
Table 3. Patients with DM were more likely to be diag-
nosed with CP at an older age compared with their non-
diabetic counterparts (p¼ 0.007). Likewise, patients
with long-lasting CP were more likely to have DM
compared with patients with short-lasting disease
(p< 0.001). Patients with dyslipidaemia (p< 0.001) as
an aetiological risk factor were more likely to have dia-
betes, whereas no differences were observed for the
remaining aetiological risk factors. In addition, patients
with a BMI in the overweight or obese categories were
more likely to have DM (p< 0.001). The presence of
EPI was more frequently observed in patients with dia-
betes (p< 0.001) and conveyed an elevated risk for DM
across all BMI categories (Figure 2). Likewise, pancre-
atic calcifications was associated with an increased DM
risk (p¼ 0.001), whereas the number of patients with a
past history of recurring acute pancreatitis (p¼ 0.70),
pancreatic resection (p¼ 0.06) and endoscopic drainage
Table 1. Patient and disease characteristics of the study
cohort (n¼ 1107).
Patient characteristics
Male gender, n (%) 750 (67)
Age at CP diagnosis, years SD 52.8 14.2
Age distribution at CP diagnosis, n (%)
<30 years 68 (6)
30–40 years 133 (12)
40–50 years 260 (23)
50–60 years 270 (24)
60–70 years 239 (21)
>70 years 147 (13)
BMI, kg/m2 SD 23.3 4.4






Duration of CP, years SD 5.0 5.9
Duration of CP, n (%)
<5 years 680 (61)
5–10 years 274 (25)
>10 years 163 (15)
Etiological risk factors, n (%)a
Alcohol 660 (59)
Nicotine 753 (67)









Exocrine pancreatic insufficiency, n (%) 569 (51)
Diabetes mellitus, n (%) 457 (41)
aPatients may have more than one etiological risk factor according to
the M-ANNHEIM classification. Concomitant alcoholic and smoking eti-
ology were seen in 529 (47%) patients.
CP: chronic pancreatitis; BMI: body mass index.
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of pancreatic fluid collections (p¼ 0.05) was propor-
tionate between patients with and without DM.
Independent parameters associated with DM
(multivariate analysis)
Results of the multivariate analysis are reported in
Table 4 and illustrated in Figure 3. On multivariate
analysis, age at diagnosis (p< 0.001), duration of CP
(p< 0.001), dyslipidaemia (p< 0.001), overweight or
obese BMI categories (p 0.002), pancreatic calcifica-
tions (p¼ 0.02), pancreatic resection (p¼ 0.02) and EPI
(p< 0.001) were confirmed as significant and independ-
ent risks factors for DM. In contrast, risk factors indi-
cative of a history of acute pancreatitis only marginally
influenced the risk of DM and did not reach statistically
significant associations (Table 4).
Discussion
We investigated the prevalence of DM and associated
risk factors in a multicentre cohort of more than 1100
patients with a definite diagnosis of CP from a
restricted geographical area. We found 40% of patients
had DM and a number of risk factors were identified
including classic CP-related risk factors indicative of
beta cell loss (EPI, pancreatic resection and calcifica-
tions). In addition, we investigated factors relating to
type 2 DM and acute pancreatitis. Although type 2
DM-related risk factors (dyslipidaemia and over-
weight/obesity) conveyed an increased and clinically
Table 3. Patient and disease characteristics in chronic pan-





(n¼ 660) p value
Male gender, n (%) 322 (71) 428 (65) 0.05
Age at CP diagnosis,
years SD
53.6 12.9 52.3 15.0 0.13
Age at CP diagnosis category, n (%)
<30 years 15 (3) 53 (8) 0.007
30–40 years 53 (12) 80 (12)
40–50 years 111 (24) 149 (23)
50–60 years 112 (25) 158 (24)
60–70 years 113 (25) 126 (19)
>70 years 53 (12) 94 (14)
Duration of CP, years SD 6.3 6.6 4.0 5.2 <0.001
Duration of CP category, n (%)
<5 years 232 (51) 448 (68) <0.001
5–10 years 125 (27) 149 (23)
>10 years 100 (22) 63 (10)
Etiological risk factors, n (%)
Alcohol 285 (62) 375 (57) 0.07
Nicotine 317 (69) 436 (66) 0.27
Nutritional (dyslipidaemia) 33 (7) 15 (2) <0.001
Hereditary 31 (7) 49 (7) 0.72
Efferent 40 (9) 66 (10) 0.53
Immunological 21 (5) 45 (7) 0.16
Miscellaneous 37 (8) 54 (8) 1.00
BMI, kg/m2 SD 23.7 5.0 22.9 3.9 <0.001
BMI category, n (%)
Underweight 52 (11) 78 (12) 0.001
Normal 242 (53) 417 (63)
Overweight 122 (27) 134 (20)
Obese 41 (9) 31 (5)
Recurring acute
pancreatitis, n (%)a
183 (45) 263 (43) 0.70
Pancreatic calcifications, n (%) 382 (84) 499 (76) 0.001
EPI, n (%) 291 (64) 278 (42) <0.001
Endoscopic therapy, n (%)
Drainage of pancreatic
fluid collection
53 (12) 53 (8) 0.05
Common bile duct stenting 70 (15) 83 (13) 0.22
Pancreatic duct stenting 76 (17) 116 (18) 0.75
Pancreatic surgery, n (%)
Pancreatic drainage procedure 16 (4) 19 (3) 0.60
Pancreatic resection 29 (6) 25 (4) 0.06
Combined drainage
and resection
12 (3) 19 (3) 0.86
aA history of recurring acute pancreatitis was undetermined in 98
patients and these were not included in the analysis.
CP: chronic pancreatitis; BMI: body mass index; EPI: exocrine pancre-
atic insufficiency.
Table 2. Chronic pancreatitis related treatment modalities in
the study cohort.





Oral and insulin 44 (10)
Endoscopic therapy, n (%)
Drainage of pancreatic fluid collection 119 (8)
Common bile duct stenting 187 (12)
Pancreatic duct stenting 204 (13)
Surgery, n (%)
Pancreatic drainage procedure 45 (3)
Pancreatic resection 59 (4)
Combined drainage and resection 32 (2)
bAmong the full patient cohort (n¼ 1107); some patients received
PERT for mild EPI (defined according to M-ANNHEIM) or other indica-
tions such as pain.
bAmong patients with diabetes mellitus (n¼ 457).
EPI: exocrine pancreatic insufficiency; PERT: pancreatic enzyme repla-
cement therapy.
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relevant risk for DM independently of the classic CP-
related risk factors, only marginal effects were observed
from the risk factors associated with acute pancreatitis
(previous history of recurring acute pancreatitis and
pancreatic fluid collections). Taken together, these find-
ings underline the heterogeneous mechanisms underly-
ing DM in CP and may have implications for the
treatment of this entity.
Prevalence of DM
The point prevalence of DM was approximately 40% in
our cohort. This number is higher than that observed in
the North American Pancreatitis Study (NAPS 2)
cohort where 282 out of 1171 (29%) had DM.3 The
reason for the higher DM proportion in our cohort
compared with the NAPS 2 study may be explained
by different inclusion criteria and longer disease dur-
ation of the patients included in our study. Hence, pro-
spective studies have shown the incidence of DM
increases with prolonged duration of CP and approxi-
mately 50% of patients have diabetes 10 years after a
diagnosis of CP has been established.4 In contrast,
some patients may develop DM after a relatively
short period of CP as illustrated by our data where
the mean duration of CP was only 5 years for the over-
all cohort; similar observations apply for the NAPS 2
study.3 Taken together, these data emphasize that DM
is a common complication of CP and not restricted to
patients with longstanding disease.
Risk factors for DM
In keeping with findings from many previous studies we
confirmed CP-related parameters (pancreatic calcifica-
tions, resection and EPI) as independent risk factors for
DM.3,4,19,20 These parameters are mostly indicators of
end-stage CP and the mechanism underlying the
increased risk of DM are likely explained by beta cell
loss, with gradual destruction of the islet cells as the
fibro-inflammatory process evolves. Importantly, this





































Figure 2. Prevalence of diabetes mellitus by body mass index (BMI) category and the presence or absence of exocrine pan-
creatic insufficiency. Percentages of patients with diabetes are shown in the figure for the individual subgroups.
Table 4. Multivariable analysis of patient and disease
characteristics and the odds of having diabetes mellitus.
Odds ratio (95% CI) p value
Male gender 1.31 (0.97–1.76) 0.07
Age at CP diagnosis (years) 1.02 (1.01–1.04) <0.001
Duration of CP (years) 1.08 (1.05–1.11) <0.001
Dyslipidaemia 4.42 (2.14–9.13) <0.001
BMI category (vs normal)
Underweight 0.96 (0.62–1.50) 0.87
Overweight 1.72 (1.23–2.40) 0.002
Obese 3.28 (1.88–5.74) <0.001
Pancreatic calcifications 1.53 (1.08–2.16) 0.02
Exocrine insufficiency 2.33 (1.75–3.10) <0.001
Pancreatic resection 2.21 (1.16–4.22) 0.02




AP: acute pancreatitis; BMI: body mass index; CI: confidence interval;
CP: chronic pancreatitis.
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process also affects the other endocrine cells in the pan-
creatic islets with concomitant destruction of alpha cells
(glucagon), delta cells (somatostatin) and pancreatic
polypeptide cells.21 The clinical correlate of this process
is a ‘brittle diabetes’ with patients experiencing highly
fluctuating blood glucose levels and increased risk of
hypoglycaemic episodes due to the lack of hormonal
counterregulation.22 This clinical phenotype is, how-
ever, only seen in a subset of patients that implies
other DM-related mechanisms are likely operative.
In addition to the classic CP-related risk factors
for DM, we confirmed the recent findings that type 2
DM-related risk factors also convey an increased
risk of diabetes in patients with CP.3,5 Hence, over-
weight or obese patients and those with dyslipidaemia
had increased risk of DM compared with their
normal-weight and normolipidemic counterparts.
Interestingly, the risk estimates (ORs) were even
higher for the type 2-related risk factors compared
with the CP-related parameters. Hence, the longstand-
ing view of DM as a consequence of beta cell loss fol-
lowing fibrosis and atrophy may need to be revisited
and reconsidered in a broader context including genetic
risk of beta cell dysfunction and insulin resistance.
Indeed, more than 400 single nucleotide polymorph-
isms have been identified and associated with an
increased risk of type 2 DM, where the majority of
disease-associated variants exert their effects through
pancreatic islet dysfunction.6,23 Hence, it is conceivable
that many patients with CP have a genetic
predisposition for DM and together with a gradual
loss of beta cells resulting from pancreatic fibrosis
and atrophy, this may ultimately lead to the develop-
ment of DM.
A novel aspect of our study was the inclusion of
acute pancreatitis-related parameters (previous history
of recurring acute pancreatitis and pancreatic fluid col-
lections) as putative risk factors for DM.7,8 We
observed marginal (and borderline significant) associ-
ations for the presence of pancreatic fluid collections
and DM risk, but no association was observed for pre-
vious attacks of acute pancreatitis. This implies the
mechanism underlying the two-fold increased risk of
DM in patients with acute pancreatitis (but without
CP) observed in population-based studies does not
seem to be operative in the majority of patients with
CP.7,8 Hence, it may be speculated that DM in the
setting of acute pancreatitis is mediated through diverse
and hitherto unrecognized mechanisms compared with
the mechanisms involved in the development of DM in
patients with CP.
Implications for treatment
The finding that type 2 DM-related risk factors are
present in many patients with CP and diabetes may
have implications for treatment. Currently there are
no international guidelines for the management of pan-
creatogenic diabetes (type 3c DM), but most expert
opinions recommend that patients are started on
Demographic risk factors
Male gender
Age at CP diagnosis (years)
Duration of CP (years)
Type II DM related risk factors
Dyslipidemia
Overweight BMI (vs normal)
Obese BMI (vs normal)




AP related risk factor
History of recurring AP
Drainage of pancreatic fluid collections
Risk factors for diabetes mellitus
Odds ratio (95% CI)
1 2 3 4 5 6 8 10 
Figure 3. Forest plot of risk factors for diabetes mellitus in patients with chronic pancreatitis (CP) obtained from multivariable
logistic regression modelling. Whiskers represent 95% confidence intervals.
BMI: body mass index; AP: acute pancreatitis; CP: chronic pancreatitis; DM: diabtes mellitus.
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metformin in the presence of mild hyperglycaemia and
shifted to insulin-based therapies in the absence of ade-
quate glycaemic control.16,22,24 This is in keeping with
the treatment modalities observed in our study where
the majority of patients were on insulin treatment. As
our understanding of the mechanisms involved in
pancreatogenic diabetes evolves, it is most likely that
additional antidiabetics, currently restricted for use in
type 2 DM, may be useful in CP as well.
Our study was not designed to investigate if the pres-
ence of diabetes was associated with an underlying
pancreatic malignancy. Recent high-quality studies
have shown that hyperglycaemia is an early marker of
pancreatic ductal adenocarcinoma.25,26 This knowledge
should be incorporated in the management algorithms
of patients with CP who have a nearly seven-fold
increased risk of pancreatic cancer compared with the
background population.27 Hence, it is suggested to do a
cross-sectional imaging study in CP patients with newly
diagnosed (or severely dysregulated) DM to rule out
the presence of an underlying malignancy. However,
the cost effectiveness of such an approach will need
validation in well-designed prospective studies.
Study limitations
A number of limitations of our study need to be men-
tioned. First, the cross-sectional study design precludes
inference of causality between the observed associ-
ations. However, type 2 DM-related risk factors have
previously been observed in patients with CP and popu-
lation-based studies support an independent associ-
ation between diabetes risk and previous attacks of
acute pancreatitis.3,5,7,8 Second, the increased preva-
lence of type 2 DM-related risk factors (overweight/
obesity and dyslipidemia) in our cohort may simply
reflect that a proportion of patients had classic type 2
DM given the high prevalence of type 2 DM in the
general Western population.28 However, within the
limitations of this large epidemiologic study, it was
not feasible to employ testing to distinguish type 2
DM from pancreatogenic diabetes. Along this line, we
did not assess whether beta cell autoimmunity (type 1
DM) was a contributor to diabetes development in our
cohort, but overall the prevalence of type 1 DM is
below 1% and thus this is less likely to influence our
findings. Third, we did not collect data on genetic risk
for DM (family history or biomarkers). However, the
aforementioned studies from the NAPS 2 consortium
have investigated this thoroughly in previous studies
and findings from these studies support our conclu-
sions.3,5 Finally, our observations are restricted to a
population dominated by alcohol and smoking related
CP mostly from the Northern European countries and
thus need further validation in populations with
different aetiological risk factor profiles and in paediat-
ric populations.29,30
Conclusion
DM in patients with CP is associated with multiple risk
factors including parameters associated with loss of
beta cell mass, but also classic type 2 DM-related risk
factors including overweight/obesity and dyslipidae-
mia. These findings attest to the understanding of
DM as a complex and multifactorial complication of
CP and have implications for management.
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